Investor confidence, reflected in a high P/S ratio and increasing share prices despite fluctuations, suggests anticipated persistent growth in Phreesia. Caution advised over sole reliance on price-to-sales ratios for investment decisions.
Gainers: •$Okta(OKTA.US)$+15.8% (In reaction to earnings) •$StoneCo(STNE.US)$+12.9% (In reaction to earnings) •$Turning Point Therapeutics(TPTX.US)$+116.8% (Bristol Myers Squibb (BMY) will acquire Turning Point Therapeutics for $76,00 per share; expected to be accretive to Non-GAAP earnings per share beginningin2025) •$Amylyx Pharmaceuticals(AMLX.US)$+24.9% (receives PDUFA date extension for AMX0035; scheduled for September ...
Upgrades •$CDW Corp(CDW.US)$: Stifel Upgrades to Buy from Hold - PT $210 (from $200) •$Corteva(CTVA.US)$: Loop Capital Upgrades to Buy from Hold - PT $69 •$美国惩教公司(CXW.US)$: Wedbush Upgrades to Outperform from Neutral - PT $17 (from $10.85) •$达美航空(DAL.US)$: Barclays Upgrades to Overweight from Equalweight - PT $60 (from $42) •$富乐(FUL.US)$: Baird Upgrades to Outperform from Neutral - PT $85 •$亨廷顿英格尔斯工业(HII.US)$: Cowen U...
Gainers: •$Clovis Oncology(CLVS.US)$+40.6% (Rubraca significantly improves progression-free survival in first-line maintenance treatment in women with ovarian cancer regardless of their biomarker status in phase 3 athena-mono trial) •$Dare Bioscience(DARE.US)$+13.61% (Organon and Dar Bioscience have entered into an agreement whereby Organon will license global rights to XACIATO) •$KULR Technology(KULR.US)$+9.5% (secured a battery sa...
Phreesia股票讨论区
专栏Today's pre-market stock movers: TSLA, CHGG, OKTA, TPTX and more
• $Okta(OKTA.US)$ +15.8% (In reaction to earnings)
• $StoneCo(STNE.US)$ +12.9% (In reaction to earnings)
• $Turning Point Therapeutics(TPTX.US)$ +116.8% (Bristol Myers Squibb (BMY) will acquire Turning Point Therapeutics for $76,00 per share; expected to be accretive to Non-GAAP earnings per share beginningin2025)
• $Amylyx Pharmaceuticals(AMLX.US)$ +24.9% (receives PDUFA date extension for AMX0035; scheduled for September ...
专栏Top upgrades and downgrades on 4/14
• $CDW Corp(CDW.US)$: Stifel Upgrades to Buy from Hold - PT $210 (from $200)
• $Corteva(CTVA.US)$ : Loop Capital Upgrades to Buy from Hold - PT $69
• $美国惩教公司(CXW.US)$ : Wedbush Upgrades to Outperform from Neutral - PT $17 (from $10.85)
• $达美航空(DAL.US)$ : Barclays Upgrades to Overweight from Equalweight - PT $60 (from $42)
• $富乐(FUL.US)$ : Baird Upgrades to Outperform from Neutral - PT $85
• $亨廷顿英格尔斯工业(HII.US)$ : Cowen U...
专栏Today's pre-market stock movers: CLVS, PATH, DARE and more
• $Clovis Oncology(CLVS.US)$ +40.6% (Rubraca significantly improves progression-free survival in first-line maintenance treatment in women with ovarian cancer regardless of their biomarker status in phase 3 athena-mono trial)
• $Dare Bioscience(DARE.US)$ +13.61% (Organon and Dar Bioscience have entered into an agreement whereby Organon will license global rights to XACIATO)
• $KULR Technology(KULR.US)$ +9.5% (secured a battery sa...
暂无评论